Comparative molecular profiling of multidrug-resistant Pseudomonas aeruginosa identifies novel mutations in regional clinical isolates from South India.
Comparative molecular profiling of multidrug-resistant Pseudomonas aeruginosa identifies novel mutations in regional clinical isolates from South India.
复制标题
DOI:
10.1093/jacamr/dlae001
复制
发表时间:
2024-02
影响因子:
3.4
通讯作者:
中科院分区:
文献类型:
--
作者:
We sought to analyse the antibiotic susceptibility profiles and molecular epidemiology of MDR clinical Pseudomonas aeruginosa isolates from South India using non-MDR isolates as a reference. We established a comprehensive clinical strain library consisting of 58 isolates collected from patients across the South Indian state of Kerala from March 2017 to July 2019. The strains were subject to antibiotic susceptibility testing, modified carbapenem inactivation method assay for carbapenemase production, PCR sequencing, comparative sequence analysis and quantitative PCR of MDR determinants associated with antibiotic efflux pump systems, fluoroquinolone resistance and carbapenem resistance. We performed in silico modelling of MDR-specific SNPs. Of our collection of South Indian P. aeruginosa clinical isolates, 74.1% were MDR and 55.8% were resistant to the entire panel of antibiotics tested. All MDR isolates were resistant to levofloxacin and 93% were resistant to meropenem. We identified seven distinct, MDR-specific mutations in nalD, three of which are novel. mexA was significantly overexpressed in strains that were resistant to the entire test antibiotic panel while gyrA and gyrB were overexpressed in MDR isolates. Mutations in fluoroquinolone determinants were significantly associated with MDR phenotype and a novel GyrA Y100C substitution was observed. Carbapenem resistance in MDR isolates was associated with loss-of-function mutations in oprD and high prevalence of NDM (blaNDM-1) within our sample. This study provides insight into MDR mechanisms adopted by P. aeruginosa clinical isolates, which may guide the potential development of therapeutic regimens to improve clinical outcomes.
登录
查看更多内容
影响因子:
3.9
作者:
Nguyen KV;Nguyen TV;Nguyen HTT;Le DV
通讯作者:
Le DV
影响因子:
5.2
作者:
Shu, Jwu-Ching;Kuo, An-Jing;Wu, Tsu-Lan
通讯作者:
Wu, Tsu-Lan
影响因子:
3.3
作者:
Murugan, Nandagopal;Malathi, Jambulingam;Madhavan, Hajib NarahariRao
通讯作者:
Madhavan, Hajib NarahariRao
影响因子:
1.9
作者:
Amudhan, M. Shanthi;Sekar, Uma;Balaraman, Sekar
通讯作者:
Balaraman, Sekar
DOI:
10.1016/s0140-6736(21)02724-0
发表时间:
2022-02-12
期刊:
Lancet (London, England)
影响因子:
--
作者:
Antimicrobial Resistance Collaborators
通讯作者:
Antimicrobial Resistance Collaborators